Showing results (1-10 of 26) with videos related to
Sort By:
Pageof 3
European Journal of Haematology|November 20, 2009
Antibody buffering of systemically administered lysozymeCarol O'Hear, Jefferson FooteJournal of Molecular Biology|October 19, 2006
Antibody buffering in the brainCarol O'Hear, Jefferson FooteExpert Review of Hematology|May 30, 2014
Recent research and future prospects for gemtuzumab ozogamicin: could it make a comeback?Carol O'Hear, Jeffrey E RubnitzProceedings of the National Academy of Sciences of the United States of America|December 24, 2004
Antibody buffering of a ligand in vivoCarol E O'Hear, Jefferson FooteMethods (San Diego, Calif.)|April 26, 2005
Immunogenicity of engineered antibodiesWilliam Ying Khee Hwang, Jefferson FooteHaematologica|December 7, 2014
Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemiaCarol O'Hear, Joshua F Heiber, Ingo Schubert, et al.Methods (San Diego, Calif.)|April 26, 2005
Use of human germline genes in a CDR homology-based approach to antibody humanizationWilliam Ying Khee Hwang, Juan Carlos Almagro, Timothy N Buss, et al.Journal of Immunology (Baltimore, Md. : 1950)|July 5, 2002
"Superhumanized" antibodies: reduction of immunogenic potential by complementarity-determining region grafting with human germline sequences: application to an anti-CD28Philip Tan, David A Mitchell, Timothy N Buss, et al.Journal for Immunotherapy of Cancer|October 25, 2019
Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumabLuciana Molinero, Yijin Li, Ching-Wei Chang, et al.The Journal of Biological Chemistry|January 28, 2006
NMR dynamic studies suggest that allosteric activation regulates ligand binding in chicken liver bile acid-binding proteinLaura Ragona, Maddalena Catalano, Marianna Luppi, et al.Pageof 3